^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FLT3 positive

    i
    Other names: FLT3, Fms Related Tyrosine Kinase 3, Receptor-Type Tyrosine-Protein Kinase FLT3, Stem Cell Tyrosine Kinase 1, Fms-Like Tyrosine Kinase 3, CD135, FLK-2, STK1, Growth Factor Receptor Tyrosine Kinase Type III, Fetal Liver Kinase 2
    Entrez ID:
    2322
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    12ms
    The Impact of Gilteritinib on Overall Survival of Adult Patients with FLT3 Positive Acute Myeloid Leukemia: A Systematic Review. (PubMed, Princ Pract Clin Res)
    Gilteritinib exhibited promising outcomes by targeting FLT3 receptors, offering a new treatment approach, and revealing improved overall survival compared to salvage chemotherapy in the difficult-to-treat patient population.
    Review • Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 positive
    |
    Xospata (gilteritinib) • azacitidine
    12ms
    Impact of COVID-19 on the Clinical Characteristics and Outcomes of Patients with Acute Leukaemia: An academic centre experience. (PubMed, Sultan Qaboos Univ Med J)
    The complete remission (P = 0.48) and the overall survival rates were similar (P >0.05). Except for an increased rate of acute leukaemia and a lower platelet count, the COVID-19 pandemic did not impact the presentation and outcomes of acute leukaemia.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1)
    |
    NPM1 mutation • FLT3 positive
    1year
    The Immunomodulatory Effect of Different FLT3 Inhibitors on Dendritic Cells. (PubMed, Cancers (Basel))
    Our results suggest different immunosuppressive effects of these three FLT3i and may, therefore, provide an additional rationale for optimal maintenance therapy after alloHSCT of FLT3-positive AML patients to prevent infectious complications and GvHD mediated by DCs.
    Journal • Immunomodulating
    |
    FLT3 (Fms-related tyrosine kinase 3) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD86 (CD86 Molecule)
    |
    FLT3 mutation • FLT3 positive
    |
    Xospata (gilteritinib) • midostaurin • Vanflyta (quizartinib)
    1year
    NCI-2018-01607: Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)
    P1/2, N=74, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    FLT3 positive
    |
    sorafenib • cyclophosphamide • fludarabine IV • busulfan • Neupogen (filgrastim)
    1year
    Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemia. (PubMed, EBioMedicine)
    In validation, MPhos outperformed the currently-used FLT3-based stratification method. Our findings have the potential to transform clinical decision-making, and highlight the important role that phosphoproteomics is destined to play in precision oncology.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation • FLT3 positive
    |
    midostaurin
    over1year
    NCI-2018-01607: Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)
    P1/2, N=74, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    FLT3 positive
    |
    sorafenib • cyclophosphamide • fludarabine IV • busulfan • Neupogen (filgrastim)
    almost2years
    Treatment Patterns and FLT3 Mutation Testing Among Patients with Acute Myeloid Leukemia in China: A Retrospective Observational Study. (PubMed, Ther Clin Risk Manag)
    Study findings showed that there was a lack of routine testing for FLT3 mutations at first diagnosis of R/R AML, and initial treatment decisions did not differ by FLT3 mutation status. Given the clinical burden of FLT3MUT, likelihood of FLT3 status changes, and emerging FLT3 inhibitors, further routine FLT3 screening is needed to optimize treatment of R/R AML.
    Observational data • Retrospective data • Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation • FLT3 positive
    almost2years
    Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS (clinicaltrials.gov)
    P2, N=22, Completed, Randy Windreich | Active, not recruiting --> Completed | Trial completion date: Nov 2023 --> Apr 2023 | Trial primary completion date: Nov 2023 --> Apr 2023
    Trial completion • Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • CD34 (CD34 molecule)
    |
    FLT3 positive
    |
    Campath (alemtuzumab) • melphalan • fludarabine IV • hydroxyurea • thiotepa • busulfan
    2years
    NCI-2018-01607: Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)
    P1/2, N=74, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial primary completion date
    |
    FLT3 positive
    |
    sorafenib • cyclophosphamide • fludarabine IV • busulfan • Neupogen (filgrastim)
    2years
    Fms-like tyrosine kinase 3 positive acute myeloid leukemia. (PubMed, Curr Opin Oncol)
    Novel drug combinations and strategies against FLT3 mutated AML are currently under investigation and will be the focus of future studies. The development of more selective and potent FLT3 inhibitors may further improve outcomes for patients with FLT3-positive AML. Monitoring minimal residual disease and overcoming resistance are key issues for the future.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation • FLT3 positive
    2years
    Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia:Updated Results from a Phase I Study (ASH 2023)
    This phase 1 study has demonstrated an acceptable safety profile and a significant anti-leukaemic activity of clifutinib in FLT3 mutant R/R AML, with the best response at the dose of 40 mg/day in FLT3-ITD(+)/TKD(-) AML. A confirmatory phase 3 study is currently ongoing to further evaluate the efficacy and safety of clifutinib dosed at 40 mg/day in R/R AML pts after first-line therapy with FLT3-ITD(+)/TKD(-) (NCT05586074).
    Clinical • P1 data
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation • FLT3 positive
    |
    clifutinib (HEC73543)